Wire · regulatory
UCB Comes to Agreement with U.S. Government to Lower the Cost of Medicine and ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 31 August 2026 · Fusion42 review
UCB has agreed with the U.S. government on measures to lower medicine costs while expanding its U.S. manufacturing footprint, including a new biologics facility in Georgia expected to create over 330 jobs and generate $5 billion in economic impact. The agreement exempts UCB from Section 232 Pharmaceutical tariffs and includes participation in the GENEROUS program to balance pricing and support patient access.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Your US market pricing just changed as UCB's new deal removes tariffs and unlocks access support while investing heavily in US manufacturing jobs. Prepare for shifting government pressure on pricing and local production requirements that reshape patient access and supply chains.
◆ Coverage
1 source · 31 Aug 2026
◆ Related on Wire
◆ Topics